Increasing the mg dose in increments to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and a maximum of 15 mg
Meanwhile, across the Atlantic, Novo Nordisk and other companies were busy engineering human GLP-1 analogues (like NN2211, which became liraglutide) using techniques such as acylation to extend half-life ( [87] ) ( [88] )
Patients who dispensed a GLP-1 RA for the first time within that same period had a run-in period of 12 months and were defined as incident patients, thus excluding patients who dispensed a GLP-1 RA in 2018 when assessing incidence in 2019
But purine correlations with 5-HIAA seem to be present only in HC subjects, not in FENNS at baseline or 4 weeks after antipsychotic treatment
Moreover, a favorable impact of GLP-1RAs on cardiac remodeling can occur through activation of the eNOS/cyclic guanosine monophosphate (cGMP)/protein kinase G (PKG) nexus [72]